Will the RCG Corporation Ltd share price rebound higher?

The RCG Corporation Ltd (ASX:RCG) share price crashes as investors head for the exit.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On Monday, shares in Australia's largest footwear retailer RCG Corporation Ltd (ASX: RCG) plummeted over 28.5% after management announced a second profit downgrade in the space of three months.

Investors spoke with their feet and headed for the exits (presumably not in Skechers), as the once high-flying owner of The Athlete's Foot, HYPE DC and the Accent Group (which in turn owns Dr Martens, Vans and Platypus shoes amongst others) said tough retail conditions continued to impact sales.

Whilst this competitive retail environment sentiment is shared by listed discretionary retailing peers OrotonGroup Limited (ASX: ORL) and Myer Holdings Ltd (ASX: MYR), I think the savage sell-off in RCG's share price may be overdone. Here's why.

Company financials

Make no mistake. Two profit downgrades in the space of a quarter is inexcusable for any company.

However, there also comes a point when investors need to look past the market noise and assess an investment on its merits. In this regard, I believe RCG's current share price stacks up well against its future prospects (and downside risks).

Earnings & profit

For the half-year ended 25 December 2016, RCG recorded a whopping 42% increase to underlying earnings (EBITDA). This translated to a 17% increase to earnings per share on the prior corresponding period.

Underlying net profit after tax (NPAT) for the half swelled 34% to $23.3 million, with like-for-like sales growing 7.6% in RCG's Accent Group division – a standout result.

However, the good news appeared to end there with management announcing in February that full-year EBITDA was likely to fall to $85 million to $88 million (down from previous guidance of $90 million).

Outlook

On Monday, RCG added to its woes by reducing full-year underlying EBITDA guidance again to $74 million to $80 million. Though this is a stark 18% departure from its guidance of $90 million at the end of FY16, investors must remember that the downgraded guidance still represents an admirable 22.5% growth rate from its 2016 full-year earnings of $60.4 million.

Strong footing

Even though the profit downgrade is nothing to be sneezed at, investors must put it in context of the near 60% drop in share price since the start of 2017.

Driving this decline is also fears of Amazon's impact on Australia's retail market. Though Amazon is a real threat for footwear retailing, I believe RCG is well placed to weather the storm given its strong brand names and vertically integrated network.

Foolish takeaway

One thing I am wary of is that profit downgrades come in droves.

As shareholders of iSentia Group Ltd (ASX: ISD) and Vocus Group Ltd (ASX: VOC) have experienced, management seldom gets profit downgrades right the first few times around. As such, there is potential for the company to announce a further downgrade if retail conditions don't pick up any time soon.

Though this is a real prospect, based on Tuesday's closing price of 70 cents per share, RCG's shares trade at a forward price-earnings of about 8.5x (if lower end of guidance is achieved) and a trailing fully-franked yield of 8.6% (if dividends are maintained). This makes it extremely cheap for a company delivering profit and earnings growth.

Accordingly, whilst risks remain around Amazon's arrival and further profit downgrades, I believe the current share price of RCG demands a closer look as a speculative buy.

Motley Fool contributor Rachit Dudhwala has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »